This article is more than 5 years old. Information may no longer be current.

Ophthotech initiates phase 1 trial of anti-PDGF aptamer for treating AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PRINCETON, N.J. — Ophthotech has enrolled the first patient in its phase 1 clinical trial of E10030, an anti-platelet derived growth factor aptamer being developed for treating wet age-related macular degeneration, according to a press release from the company.

The trial will evaluate the safety and tolerability of E10030 in combination with an anti-VEGF agent in up to 36 patients.

"The current treatment regimen for angiogenesis in AMD does not result in neovascular regression. The combination of anti-PDGF (anti-platelet derived growth factor) and anti-VEGF agents has been shown to cause neovascular regression, in both ocular and tumor angiogenesis preclinical models. We believe E10030 holds great promise for enhancing the visual outcome for patients with AMD," Samir Patel, MD, president and CEO of Ophthotech, said in the release.

E10030 is the first of three compounds - including ARC1905 and volociximab (M200) - that Ophthotech is developing to treat AMD.